Vertex Pharmaceuticals made a big financial commitment to expand its cystic fibrosis portfolio beyond drugs for patients with specific genetic mutations to gene-editing therapies that may cure CF via a new partnership with CRISPR Therapeutics that more than doubles the startup firm's cash balance.
Boston-based Vertex will pay $105m up front, including a $30m equity investment in CRISPR, to develop therapies based on clustered,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
